Page last updated: 2024-11-08

triostin a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

triostin A: RN given refers to triostin A; see also record for triostin C [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID316447
CHEMBL ID2007041
MeSH IDM0100032

Synonyms (10)

Synonym
triostin a
NSC244425 ,
b100928k382
nsc-244425
13758-27-5
l-valine, bimol. lactone, cyclic disulfide
NCI60_001953
n-[(1s,4s,7r,11s,14s,17s,20r,24s)-2,4,12,15,17,25-hexamethyl-3,6,10,13,16,19,23,26-octaoxo-11,24-di(propan-2-yl)-20-(quinoxaline-2-carbonylamino)-9,22-dioxa-28,29-dithia-2,5,12,15,18,25-hexazabicyclo[12.12.4]triacontan-7-yl]quinoxaline-2-carboxamide
n-[2,4,12,15,17,25-hexamethyl-3,6,10,13,16,19,23,26-octaoxo-11,24-di(propan-2-yl)-20-(quinoxaline-2-carbonylamino)-9,22-dioxa-28,29-dithia-2,5,12,15,18,25-hexazabicyclo[12.12.4]triacontan-7-yl]quinoxaline-2-carboxamide
CHEMBL2007041

Research Excerpts

Overview

Triostin A is a bicyclic depsipeptide with very potent antitumoral activity because of its bisintercalation into DNA. It is a biosynthetic precursor of echinomycin which is one of the most potent HIF-1 inhibitors.

ExcerptReferenceRelevance
"Triostin A is a symmetric bicyclic depsipeptide with very potent antitumoral activity because of its bisintercalation into DNA. "( Solid-Phase Synthesis of Triostin A Using a Symmetrical Bis(diphenylmethyl) Linker System.
Lim, D; Sable, GA, 2015
)
2.16
"Triostin A is a biosynthetic precursor of echinomycin which is one of the most potent hypoxia inducible factor 1 (HIF-1) inhibitors. "( Solution-phase synthesis and biological evaluation of triostin A and its analogues.
Ebihara, M; Hattori, K; Hirayama, T; Koike, K; Nagasawa, H; Okuda, K; Takenaka, M, 2016
)
2.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (46)

TimeframeStudies, This Drug (%)All Drugs %
pre-199017 (36.96)18.7374
1990's13 (28.26)18.2507
2000's10 (21.74)29.6817
2010's6 (13.04)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 15.59

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index15.59 (24.57)
Research Supply Index3.89 (2.92)
Research Growth Index4.30 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (15.59)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (6.25%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other45 (93.75%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]